AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03533036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: applied VR headset
Description: Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
Study NCT02850887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general endotracheal anesthesia
Description: sedation with the use of endotracheal intubation
Study NCT02850887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep sedation without endotracheal intubation
Description: deep sedation without endotracheal airway management.
Study NCT01345123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of condition specific shared decision making (SDM) aids only
Description: Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
Study NCT01345123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic outreach and support by Health Coach
Description: Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
Study NCT00657631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999).
Study NCT01661361 — intervention group
Intervention type: PROCEDURE
Intervention: blood levels
Study NCT01763905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Subcutaneous injection
Study NCT00920686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXN-188
Description: NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
Study NCT00920686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered as 3 placebo hard gelatin capsules
Study NCT01763905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Subcutaneous injection
Study NCT01763905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration
Study NCT01763905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Tablet for oral administration
Study NCT03219749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
Study NCT00137852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
Study NCT00920686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate
Description: administered in a hard gelatin capsule with 2 capsules of placebo
Study NCT03899818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting balloon
Description: Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
Study NCT03899818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting stent
Description: Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
Study NCT04012853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
Study NCT04008836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-PLUS Meter
Description: Blood Glucose Monitoring System (BGMS)
Study NCT01230619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
Study NCT01230619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
Study NCT02327104 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
Study NCT02327104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
Study NCT02327104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brazilian Ministry of Health Protocol
Description: The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
Study NCT01559480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel
Description: Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
Study NCT01559480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule takes 1 capsule before bedtime for 6 months
Study NCT03504644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03504644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03504644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT03504644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03504644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT02697539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mHA
Description: microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
Study NCT00932594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjust the TMJ Pressure to Normal Value
Description: Adjust the TMJ Pressure by the Operation Only Once for Each Patient
Study NCT03504644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Liposomal
Description: Given IV
Study NCT03504644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01192542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: Prototype silicone hydrogel contact lens
Study NCT01192542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: enfilcon A lens
Description: Marketed silicone hydrogel contact lens
Study NCT01228448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: In-Room PET scan
Study NCT00802490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-Computer Interface System
Description: Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
Study NCT00802490 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Brain-Computer Interface System
Description: Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
Study NCT04533464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: Intravenous Infusion
Study NCT00932594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Do not adjust the pressure of TMJ
Description: Do the treatments normally without additional treatment
Study NCT04533464 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion
Study NCT03236064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
Study NCT02797249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
Study NCT02797249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blank
Description: Routine examination during pregnancy.
Study NCT04370782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
Study NCT04370782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
Study NCT04370782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc sulfate 220mg once daily for 5 days
Study NCT04370782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 200 mg once daily for 5 days
Study NCT02633358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia group
Description: Therapeutic hypothermia
Study NCT00137852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
Study NCT00606580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 topical cream
Description: WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
Study NCT00606580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Alone topical cream
Description: The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
Study NCT00606580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle placebo cream
Description: Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
Study NCT02513238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cell
Description: Stemcells injected into submandibularis
Study NCT02513238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Study NCT02623868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 50mg 2Tabs.
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.
Study NCT02623868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Tab.
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.
Study NCT04325646 — intervention group
Intervention type: OTHER
Intervention: Human Biological samples
Description: Blood samples, saliva, nasopharyngeal swab for serological tests
Study NCT02623868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg 1Cap.
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Study NCT00089414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol/Drospirenone
Description: Drug administered dependent upon arm.
Study NCT00089414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol/Drospirenone
Description: Drug administered dependent upon arm.
Study NCT00089414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00089414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB 2914
Study NCT02925923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
Study NCT02925923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
Study NCT02925923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02221830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
Study NCT02221830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention utilizes a Placebo Camparator
Study NCT01262131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic therapy protocol A
Description: Application of magnetic fields using the Resonator device Protocol A
Study NCT01262131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic therapy Protocol B
Description: Application of magnetic fields using the Resonator device Protocol B
Study NCT01262131 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo therapy
Description: Application of inactive magnetic fields using the Resonator device
Study NCT05210673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
Study NCT05210673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non ERAS pathway
Description: standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
Study NCT01403181 — intervention group
Intervention type: DRUG
Intervention: Boceprevir
Description: In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data.
Study NCT02095977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fluoroscopy
Description: Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
Study NCT02095977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: synchronized high-voltage shock
Description: If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist.
Study NCT02095977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Holter monitor
Description: Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
Study NCT00560105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Flute
Description: 8 weeks home use, twice daily
Study NCT00560105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acapella
Description: 8 weeks home use, twice daily
Study NCT01517074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection
Study NCT03616626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Once Daily APBI
Description: Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
Study NCT00137852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
Study NCT00137852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 5 days a week for 5-6 weeks
Study NCT00137852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Within 4-8 weeks of chemoradiation therapy
Study NCT01675011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene® Microspheres
Study NCT01675011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere®
Study NCT03504774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cashew or Shrimp Oral Immunotherapy
Description: All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
Study NCT06128005 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: knowledge translation in nursing for pressure injury care
Description: Pressure injury's knowledge and healing of wound.
Study NCT06128005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge translation in nursing for pressure injury care
Description: Pressure injury's knowledge and healing of wound.
Study NCT02220348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Study NCT04022811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac
Description: the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.